Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain — DELISA

Cow's Milk Protein Allergy Clinical Trial

Official title:
Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain

Status Completed

Clinical Trial Summary

Damira 2000© is a 100% extensive casein hydrolysate (eHCF). It is formulated to help reverse growth retardation as a result of cow's milk proteins allergy (CMPA), to be well tolerated and to help improve symptoms.Damira 2000 is indicated for allergy/intolerance to cow's milk proteins, atopic dermatitis secondary to CMPA, intestinal malabsorption processes and prevention of allergy/intolerance to cow's milk proteins.The study aimed at evaluating the tolerance of Damira 2000 in a cohort of children with CMPA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06273371
Study type	Observational
Source	Lactalis
Contact
Status	Completed
Phase
Start date	December 12, 2023
Completion date	December 21, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04596059` - The Journey of Children With Cow's Milk Protein Allergy in Mexico.
Not yet recruiting	`NCT06130085` - Partially Hydrolyzed Formula in Cow's Milk Protein Allergy After 6 Months of Elimination	N/A
Completed	`NCT03769051` - Study on The Oral Immune Tolerance of CMPA Infants Using Amino Acid Formula
Completed	`NCT02953223` - A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Completed	`NCT03085134` - Clinical Safety & Efficacy of a New Infant Formula With Specific Medical Purpose Containing Human Milk Oligosaccharides	N/A
Recruiting	`NCT06288503` - Hydrolysed Rice Formula Study	N/A